Karyopharm Therapeutics (NASDAQ: KPTI) recently received a number of ratings updates from brokerages and research firms: 7/13/2019 – Karyopharm Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs […]
